Bayer Aktiengesellschaft earned an A grade for Momentum in Zacks Style Scores, reflecting three consecutive quarters of accelerating sales growth. In its latest report, the company posted a 6.2% year-over-year increase in revenue for the third quarter, driven by gains in its crop science and consumer health segments. Analysts point to a sustained uptrend in institutional buying, with average daily trading volume rising by 18% over the past six months. This momentum rating positions BAYRY favorably for investors seeking exposure to a diversified life-sciences platform experiencing accelerating top-line trends.

Bayer’s agricultural arm, Monsanto, filed suit in Delaware federal court against Pfizer, BioNTech and Moderna, alleging unauthorized use of its proprietary messenger RNA delivery methods in COVID-19 vaccine production. The complaint cites four U.S. patents granted between 2017 and 2020, valued at an estimated €200 million annually in potential licensing fees. Bayer is seeking injunctive relief and damages, which could range into the low hundreds of millions of euros if Bayer prevails. The action underscores Bayer’s strategy to monetize its intellectual property and could bolster future earnings if licensing agreements are reached.